Diabetes mellitus after stem cell transplantation in a patient with acute lymphoblastic leukemia: Possible association with tacrolimus
暂无分享,去创建一个
T. Nakahata | Michihiro Kobayashi | H. Hiramatsu | Kenichiro Watanabe | K. Umeda | A. Niwa | H. Fujino | H. Matsubara | T. Yorifuji | M. Shiota | S. Adachi | Y. Higashi
[1] F. Birg,et al. Autoimmune polyendocrine failure — Type 1 (insulin-dependent) diabetes mellitus and hypothyroidism — after allogenic bone marrow transplantation in a patient with lymphoblastic leukaemia , 1993, Diabetologia.
[2] K. Ozono,et al. Tacrolimus-Related Encephalopathy following Allogeneic Stem Cell Transplantation in Children , 2005, International journal of hematology.
[3] C. Mathieu,et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. , 2001, Transplantation.
[4] D. Walker,et al. Adverse metabolic and cardiovascular risk following treatment of acute lymphoblastic leukaemia in childhood; two case reports and a literature review , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[5] U. Saarinen-Pihkala,et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood , 2000, The Lancet.
[6] J. Fink,et al. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] B. Griffith,et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. , 1999 .
[8] H. Mugishima,et al. Late-onset unilateral renal dysfunction combined with non-insulin-dependent diabetes mellitus and bronchial asthma following allogeneic bone marrow transplantation for acute lymphoblastic leukemia in a child , 1998, Bone Marrow Transplantation.
[9] H. Kolb,et al. Transfer of diabetes type 1 by bone-marrow transplantation , 1998, The Lancet.
[10] J. Armitage,et al. Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation. , 1990, Bone Marrow Transplantation.